🇺🇸 FDA
Patent

US 8809341

2,4-pyrimidinediamine compounds and uses as anti-proliferative agents

granted A61KA61K31/4353A61K31/505

Quick answer

US patent 8809341 (2,4-pyrimidinediamine compounds and uses as anti-proliferative agents) held by Rigel Pharmaceuticals, Inc. expires Mon Aug 14 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Aug 19 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 14 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
26
CPC classes
A61K, A61K31/4353, A61K31/505, A61K31/506, A61P